V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320004110 | 320002524 | 1.63 | 0 | Curative (C) | 2018-06-01 | 2018-06-01 | VIDE | 02 | N | 320018755 | TRIAL |
| 320004111 | 320002525 | 1.6 | 80.4 | Palliative (P) | 2015-08-04 | 2015-08-10 | Cetuximab 7 day (>Cycle 2) | N | N | 320018779 | CETUXIMAB + CISPLATIN + FU |
| 320004112 | 320002526 | 1.98 | 73.2 | Palliative (P) | 2013-10-04 | 2013-10-11 | GEMCITABINE | N | N | 320018848 | CETUXIMAB |
| 320004113 | 320002526 | null | null | Not known (9) | 2017-04-15 | 2017-05-03 | ECX | N | N | 320018848 | CARBO + FLUOROURACIL |
| 320004115 | 320002528 | 1.55 | 54 | Adjuvant (A) | 2015-02-21 | 2015-02-21 | Capecitabine + Cisplatin | 02 | N | 320018907 | LIPOSOMAL DOXORUBICIN |
| 320004116 | 320002529 | 1.64 | 0 | Curative (C) | 2017-01-22 | 2017-02-12 | Cetuximab + Radiotherapy Maint | 02 | N | 320018927 | CARBOPLATIN + ETOPOSIDE |
| 320004117 | 320002529 | 1.5 | 54 | Palliative (P) | 2015-09-27 | 2015-09-27 | Cisplatin + Docetaxel +Fluorouracil | Y | null | 320018927 | CISPLATIN + GEMCITABINE |
| 320004118 | 320002530 | 1.66 | 64 | Palliative (P) | 2014-04-29 | 2014-05-14 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | Y | 320018961 | CARBO + FLUOROURACIL |
| 320004119 | 320002530 | 1.79 | 82 | Not known (9) | 2016-03-26 | 2016-03-26 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320018961 | CARBO + FLUOROURACIL |
| 320004120 | 320002531 | 1.65 | null | Palliative (P) | null | 2014-12-13 | Bevacizumab+Carbo+Pacliaxel | 02 | N | 320019153 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320004121 | 320002531 | 1.83 | 82.4 | Palliative (P) | 2014-08-25 | 2014-09-13 | MITOMYCIN | N | N | 320019153 | DACARBAZINE |
| 320004122 | 320002532 | 1.73 | 89 | Disease modification (D) | 2016-05-21 | 2016-06-12 | CARBOPLATIN + RT | N | N | 320019157 | CARBO + FLUOROURACIL |
| 320004123 | 320002533 | 1.7 | 65.5 | Palliative (P) | 2016-02-09 | 2016-02-11 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 320019187 | CISPLATIN + GEMCITABINE |
| 320004124 | 320002534 | 1.63 | 71.6 | Adjuvant (A) | 2018-01-31 | 2018-02-01 | POUT TRIAL | N | N | 320019298 | TEMOZOLOMIDE |
| 320004125 | 320002535 | 1.42 | 109 | Neo-adjuvant (N) | 2015-09-30 | 2015-10-12 | CISPLATIN + GEMCITABINE | N | N | 320019368 | FLUOROURACIL + MITOMYCIN + RT |
| 320004126 | 320002536 | 1.61 | 45.7 | Palliative (P) | 2016-01-03 | 2016-08-05 | LIPOSOMAL DOXORUBICIN | N | N | 320019386 | PAZOPANIB |
| 320004127 | 320002537 | 1.64 | 0 | Palliative (P) | 2016-12-21 | 2016-12-24 | CISPLATIN + ETOPOSIDE | N | N | 320019392 | CAPECITABINE + CARBOPLATIN |
| 320004129 | 320002539 | 0 | 72 | null | 2018-03-08 | 2018-03-22 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | 320019483 | ICON8B TRIAL |
| 320004130 | 320002540 | 0 | null | Neo-adjuvant (N) | 2013-10-20 | 2013-11-22 | Cisplatin + Docetaxel +Fluorouracil | N | null | 320019528 | NOT MATCHED |
| 320004131 | 320002541 | 1.76 | 50 | Palliative (P) | 2014-03-11 | 2018-06-09 | EOX | N | N | 320019538 | CARBOPLATIN + DOCETAXEL |
| 320004132 | 320002542 | 1.61 | null | Palliative (P) | 2017-04-08 | 2017-04-08 | PEMBROLIZUMAB | 02 | N | 320019564 | CISPLATIN + GEMCITABINE |
| 320004133 | 320002543 | 1.55 | 65 | Palliative (P) | 2017-08-13 | 2017-09-09 | POUT TRIAL | 2 | N | 320019571 | CISPLATIN + GEMCITABINE |
| 320004134 | 320002544 | null | 58.7 | Palliative (P) | 2017-06-22 | 2017-07-14 | Liposomal Doxorubicin 50mg/m2 | N | N | 320019595 | CAPECITABINE + OXALIPLATIN |
| 320004135 | 320002545 | 1.8 | 70.7 | Palliative (P) | 2015-11-27 | 2015-12-02 | Carboplatin + Vinorelbine Oral | Y | N | 320019712 | CHOP R |
| 320004136 | 320002546 | 1.72 | 118 | Neo-adjuvant (N) | 2015-10-28 | 2015-11-03 | Ipilimumab | 2 | N | 320020042 | CETUXIMAB + RT |
| 320004137 | 320005146 | 1.62 | 40 | null | 2016-03-10 | 2016-03-11 | Trial Unspecified | N | N | 320020239 | BCG |
| 320004138 | 320002547 | 1.57 | 52.3 | Curative (C) | 2014-12-09 | 2014-12-18 | Trial Unspecified | N | N | 320020858 | BEVACIZUMAB |
| 320004139 | 320005147 | null | null | Palliative (P) | 2014-06-13 | 2014-06-24 | Cisplatin + Fluorouracil + RT 5day | N | N | 320020927 | BLEOMYCIN |
| 320004140 | 320002548 | null | 54.7 | Neo-adjuvant (N) | null | 2016-07-21 | Doxorubicin + Ifosfamide | null | null | 320021095 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 320004141 | 320002549 | 1.71 | 59.2 | Adjuvant (A) | null | 2016-05-31 | Bevacizumab+Carbo+Pacliaxel | null | null | 320021182 | CARBOPLATIN + VINCRISTINE |
| 320004142 | 320002550 | 1.7 | 58.9 | Palliative (P) | 2014-12-28 | 2015-01-14 | TIP | N | N | 320021184 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004143 | 320005148 | 1.51 | 82 | Palliative (P) | 2015-03-20 | 2015-03-21 | Carboplatin + Pemetrexed | 01 | N | 320021189 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 320004144 | 320002551 | 1.68 | 56.9 | Palliative (P) | 2015-09-01 | 2015-09-07 | EVEROLIMUS | 02 | N | 320021194 | ICON8B TRIAL |
| 320004145 | 320002552 | 0 | 70.1 | Disease modification (D) | 2017-05-09 | 2017-05-24 | Capecitabine | N | N | 320021199 | BEVACIZUMAB |
| 320004146 | 320002553 | 0 | 81.2 | Curative (C) | 2017-02-06 | 2017-02-25 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | N | 320021206 | EVEROLIMUS |
| 320004147 | 320002554 | 1.61 | 68 | Palliative (P) | 2017-09-01 | 2017-09-03 | Bevacizumab + Irinotecan + MdG | N | N | 320021218 | BEVACIZUMAB + IRINOTECAN + MdG |
| 320004148 | 320002555 | 1.63 | 57.7 | Curative (C) | 2017-01-17 | 2017-01-18 | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 02 | N | 320021222 | CVD |
| 320004149 | 320002556 | null | 54 | Neo-adjuvant (N) | 2013-07-11 | 2013-07-18 | ICON8 TRIAL | N | N | 320021235 | PEMBROLIZUMAB |
| 320004150 | 320002557 | 1.84 | 70.3 | Curative (C) | 2014-10-06 | 2014-11-01 | TEMOZOLOMIDE | 02 | Y | 320021251 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004151 | 320005149 | 1.82 | 69.199 | Adjuvant (A) | 2015-07-22 | 2015-08-19 | CISPLATIN + DOCETAXEL + FLUOROURACIL | null | N | 320021260 | ICON TRIAL |
| 320004152 | 320005149 | 1.54 | 53.5 | Curative (C) | 2018-04-01 | 2018-04-01 | BCG Intravesical | N | N | 320021260 | SORAFENIB |
| 320004153 | 320005149 | 1.68 | 59.4 | Palliative (P) | 2017-07-07 | 2017-07-07 | ICON8 TRIAL | N | N | 320021260 | CARBOPLATIN + LIPOSOMAL DOX |
| 320004154 | 320002558 | 1.68 | 98 | Palliative (P) | 2017-10-13 | 2017-10-28 | CAPECITABINE + CARBOPLATIN + Cetuximab | null | N | 320021324 | CARBOPLATIN + LIPOSOMAL DOX |
| 320004155 | 320002559 | 1.6 | 51.4 | Palliative (P) | 2016-09-07 | 2016-09-17 | Trial Unspecified | 01 | N | 320021327 | CARBOPLATIN + RT |
| 320004156 | 320002560 | null | null | Curative (C) | 2017-08-12 | 2017-08-29 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 320021340 | ICON8B TRIAL |
| 320004157 | 320005150 | 1.64 | 92 | Curative (C) | 2016-09-13 | 2016-09-18 | Vinflunine | 2 | N | 320021378 | ECX |
| 320004158 | 320002561 | 1.85 | 82.8 | Adjuvant (A) | 2016-02-06 | 2016-02-23 | Cisplatin+Gemcitabine (Days 1&8&15) | 02 | N | 320021379 | POUT TRIAL |
| 320004159 | 320002562 | -1 | 58.2 | Adjuvant (A) | 2015-12-14 | 2016-01-04 | CARBOPLATIN + ETOPOSIDE | N | N | 320021389 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004160 | 320002563 | 1.77 | 85.6 | Disease modification (D) | 2018-04-07 | 2018-04-07 | BCG Intravesical | N | N | 320021395 | CAPECITABINE |
| 320004161 | 320005151 | 1.67 | 65.7 | Palliative (P) | 2015-12-08 | 2015-12-18 | CARBOPLATIN + Cetuximab + FLUOROURACIL | Y | N | 320021396 | MITOMYCIN INTRAVESICULAR |